Drug evaluation: The MTP inhibitor JTT-130 as a potential treatment for hyperlipidemia
- PMID: 16821163
Drug evaluation: The MTP inhibitor JTT-130 as a potential treatment for hyperlipidemia
Abstract
Japan Tobacco Inc is developing JTT-130, an orally active microsomal triglyceride transfer protein inhibitor, for the potential treatment of hyperlipidemia. By August 2005, the compound was undergoing a phase II clinical trial in Japan, as well as a phase I trial in Europe.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical